Menu Back to Pharmacovigilance-and-Risk-Management-Strategies-Conference

Overview

January 26: Short Courses
January 27-29: Conference


DIA's Pharmacovigilance and Risk Management Strategies Conference provides the strongest context, background, updates, new developments, and future direction for regulations and guidance on safety, pharmacovigilance, and risk management strategies that cannot be found in any other meeting. The content of this event is developed by top experts from the biopharmaceutical industry and global regulatory agencies, and DIA will convene the best speakers from around the world to discuss the current challenges and issues that matter most to professionals working in the field.

This conference will give you the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs, rather than the cookbook approaches often presented elsewhere. In addition to new developments and updates on regional regulations and guidelines, regulators from the US, EU, and other global regions provide the context and thinking behind evolving requirements.

While we work diligently to get the 2020 agenda on the web, check out our !
program
from the 2019 event to get an idea of what’s to come!


As an MD with over 15 years of experience in drug safety and pharmacovigilance, I found the meeting one of the best in the industry. – Previous Attendee

This conference provides current and forward thinking thoughts on pharmacovigilance and risk management. It also provides an opportunity to meet colleagues from around the world in this field. – Previous Attendee

Who should attend?

Professionals with intermediate to advanced knowledge of, and experience in, clinical safety and who are involved in:

  • Drug Safety/Pharmacovigilance
  • Risk Management, including Risk Evaluation and Mitigation Strategies (REMS)
  • Benefit-risk assessment and communication
  • Medical Product Safety Assessment
  • Regulatory Affairs
  • Clinical Research
  • Pharmacoepidemiology
  • Post-market studies and Real World Evidence generation
  • Customer Engagement Programs, including Patient Support Programs
  • Medical Information, Medical Communications
  • Health Outcomes

It is also designed for professionals who work for:

  • Industry: pharmaceuticals, biologics, combination products, devices
  • Clinical Research Organizations
  • Academic Research Centers
  • Regulatory Agencies

Program Committee

  • Stella  Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP
    Stella Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP Vice President, Global Head of Early Access and Risk Management
    IQVIA, United Kingdom
  • William  Gregory, PhD
    William Gregory, PhD Worldwide Medical and Safety
    Pfizer Inc, United States
  • Mariette  Boerstoel-Streefland, MD
    Mariette Boerstoel-Streefland, MD Senior Vice President, Global Drug Safety
    Alexion, United States
  • Cheryl  Campbell, MS
    Cheryl Campbell, MS Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
    FDA, United States
  • Mick  Foy
    Mick Foy Head of Pharmacovigilance Strategy, Vigilance Intelligence, and Research Group
    Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
  • E. Stewart  Geary, MD
    E. Stewart Geary, MD Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ
    Eisai Co., Ltd., Japan
  • Stephen  Knowles, MD, MRCP
    Stephen Knowles, MD, MRCP Vice President, Drug Safety and Pharmacovigilance
    Halozyme Therapeutics, United States
  • Barbara  Morollo
    Barbara Morollo Pharmacovigilance and Risk Management Consultant
    United States
  • Michael  Richardson, MD, FFPM
    Michael Richardson, MD, FFPM International GPV&E and EU QPPV
    Bristol-Myers Squibb, United Kingdom
  • Annette  Stemhagen, DrPH, FISPE
    Annette Stemhagen, DrPH, FISPE SVP & Chief Scientific Officer
    UBC, United States
Load More

Contact us

Customer Service

1.888.257.6457


Digital Learning Catalog

DIA Learning: eLearning Soultions
Download